This study was designed to identify a novel peptide derived from soybean protein that induces inhibition of cholesterol absorption in vivo. VAWWMY (Val-AlaTrp-Trp-Met-Tyr, designated soystatin) had a significantly greater ability to bind bile acid than soybean protein peptic hydrolysate (SPH) or casein tryptic hydrolysate (CTH). Surprisingly, the bile-acid binding ability of VAWWMY was almost as strong as that of the hypocholesterolemic medicine cholestyramine. The micellar solubility of cholesterol was significantly lower in the presence of VAWWMY than in that of SPH or CTH. We found that soystatin derived from soybean glycinin acted as an inhibitor of cholesterol absorption in vivo.
Hyperlipidemia, especially hypercholesterolemia, is a very important risk factor of heart disease and ischemic heart disease. [1] [2] [3] The death rates from ischemic heart disease, including those from angina pectoris and myocardial infarction associated with coronary arteriosclerosis, have been rising at a remarkable rate. The prevention and improvement of hypercholesterolemia by dietary regulation are considered very important 4, 5) and the hypocholesterolemic action of dietary protein plays a crucial role in dietary regulation. A study of the effects of dietary protein on serum cholesterol has shown that vegetable proteins (e.g., soybean protein) reduce serum cholesterol relatively more than animal proteins (e.g., milk casein). 6) Other studies have indicated that the ingestion of soybean protein reduces serum cholesterol and triglycerides in human and experimental animals, while simultaneously reducing the accumulation of cholesterol and triglycerides in the liver. [7] [8] [9] [10] [11] In a previous study by our group, feeding with the soybean protein peptic hydrolysate (SPH) was found to reduce the serum total cholesterol concentration significantly compared with casein feeding in rats, 12, 13) and to suppress cholesterol absorption more than casein tryptic hydrolysate (CTH) in rats and Caco-2 cells.
13) Based on in vivo animal experiments and in vitro assays on the micellar solubility of cholesterol and bile-acid binding ability, we have proposed that suppression of cholesterol absorption by direct interaction between cholesterol-mixed micelles and SPH in the intestinal epithelia contributes to the hypocholesterolemic action induced by SPH. 13) Research to date has yet to identify a soy-protein derived peptide that inhibits cholesterol absorption in vivo. Indeed, we have no direct in vivo evidence that a specific peptide contributes to the inhibition of cholesterol absorption induced by soybean protein feeding. A correlation has been found, however, between the hydrophobicity of protein hydrolysate, the bile acidbinding ability of the hydrolysate, and the plasma cholesterol level. 14) Makino et al. have isolated and characterized a bile acid-binding protein from soybean glycinin. 15, 16) Based on their findings, they proposed that the A1a and A2 chains of the A1aB1b and A2B1a subunits have bile-acid binding ability after the soybean protein is trypsinized, and that the region of 114-161 residues in the A1a chain is responsible for the bile acidbinding ability in vitro. 16) However, this isolated bileacid binding protein has not been applied in animal experiments in vivo. Choi et al. 17) suggested that the VAWWMY containing region (129-134) in the A1a polypeptide (114-161) of the soybean glycinin A1aB1b subunit with high hydrophobicity is important to a bileacid binding ability in vitro using the soybean glycinin A1aB1b and A3B4 subunits but not VAWWMY peptide. To date, there is no direct evidence that the VAWWMY peptide confers bile-acid binding ability in vitro and inhibits cholesterol absorption in vivo.
In this study, we conducted in vivo studies on cholesterol absorption in rats and in vitro assays on the micellar solubility of cholesterol and the bile-acidbinding ability of the VAWWMY peptide.
VAWWMY (Val-Ala-Trp-Trp-Met-Tyr) peptide (98% purity) was purchased from the Peptide Institute (Osaka, Japan). Casein tryptic hydrolysate (CTH) was generously supplied by the Central Research Institute of Meiji Dairy Products (Odawara, Japan). The chemical composition of CTH was as follows (g/kg): protein, 862; ash, 47; moisture, 91; lipids, 0; sugar, 0. Soybean protein peptic hydrolysate (SPH) was generously supplied by Kyowa Hakko Kogyo (Tsukuba, Japan). The chemical composition of SPH was as follows (g/kg): protein, 819; ash, 100; moisture, 19; lipids, 0; sugar, 62.
Male rats of the Wistar strain (Japan SLC, Hamamatsu, Japan) were used in the animal experiments. The room temperature was maintained at 22 AE 2 C under a 12-h light dark cycle (lights on from 08:00 to 20:00 h). The Animal Care and Use Committee of Gifu University approved the animal experiments. All of the rats were housed individually in metal cages and y To whom correspondence should be addressed. Tel/Fax: +81-58-293-2931; E-mail: nagaoka@gifu-u.ac.jp Abbreviations: CTH, casein tryptic hydrolysate; SPH, soy protein peptic hydrolysate; CYP7A1, cholesterol 7-hydroxylase were allowed free access to food and water. The procedures for the animal experiments are described in detail below.
The abilities of VAWWMY, SPH, CTH, and cholestyramine (Sigma, St. Louis, USA) to bind with taurocholate were measured by a method described previously. 13) Mixtures containing 1.85 kBq of tauro [carbonyl-
14 C] cholic acid (sodium salt) (Amersham International, Buckinghamshire, UK), 0.1 mol/l sodium taurocholate in 2 ml of 0.1 mol/l Tris-HCl buffer (pH 7.4), and binding substance (VAWWMY, SPH, CTH or cholestyramine, 25 g/l) were incubated at 37 C for 2 h, and the radioactivity in the supernatant (15;000 Â g for 15 min) was measured by liquid scintillation counting.
The micellar solubility of cholesterol with VAWWMY, SPH, CTH, and cholestyramine in vitro was measured by previously described method. 13) [ 14 C]-labeled micellar solutions (1.0 ml) were prepared at the following concentrations, and were mixed by sonication: 0.74 kBq [4- 14 C]-cholesterol (2.1 Gbq/mmol, NEN, Boston, MA), 0.1 mmol/l cholesterol (Sigma), 6.6 mmol/l sodium taurocholate (Sigma), 1 mmol/l oleic acid (Sigma), 0.6 mmol/l phosphatidylcholine (Sigma), 0.5 mmol/l monoolein (Sigma), and 15 mmol/l sodium phosphate (pH 7.4). After incubation at 37 C for 24 h, VAWWMY, SPH, CTH, or cholestyramine (10 g/l) was added to the micellar solution, dispersed by sonication, incubated at 37 C for 1 h, and centrifuged at 100;000 Â g for 60 min at 37 C. The supernatant was collected for determination of [
14 C]-cholesterol by a liquid scintillation counter.
Cholesterol absorption in rats in vivo was measured by previously described method. 13, 18) After acclimation to a commercial nonpurified diet (MF, Oriental Yeast, Tokyo) for 3 d, 9-week-old rats weighing 185-205 g were deprived of food for 48 h, without restriction of their access to water. Next, the rats received the test solutions by intragastric intubation with a polyethylene catheter. One hour later, they were anesthetized with diethyl ether and killed. Blood was collected by cardiac puncture for separation of the serum, and the liver and intestines were quickly excised. The liver was rinsed with ice-cold saline, and the luminal contents of the small intestine were flushed out with ice-cold saline. The test solutions consisted of 1 mmol/l monoolein (Sigma), 3 H]-cholesterol incorporated into the serum, liver, and intestine was extracted with hexane after saponification with KOHethanol. Aliquots of the organic extract were used for scintillation counting.
The results were expressed as means and SEM. Statistical significance of differences was evaluated by Student's t-test 19) and Duncan's multiple range test. 20) VAWWMY and SPH had a significantly greater ability to bind bile acid than CTH in vitro. The bile-acid binding ability of VAWWMY was almost equal to that of the hypocholesterolemic medicine cholestyramine (Fig. 1A) .
The micellar solubility of cholesterol was significantly lower in the presence of VAWWMY, of SPH, and of cholestyramine than in the presence of CTH (Fig. 1B) .
Incorporation of [ 3 H]-cholesterol into the serum, liver, and intestines was significantly lower in the VAWWMY and the SPH group than in the CTH group (Table 1) .
A previous report 21) has hypothesized that soybean peptides that induce inhibition of cholesterol absorption exist and influence the serum cholesterol concentration. Yet none of the earlier investigations has found a peptide derived from soybean protein that inhibits cholesterol absorption. Many studies have been conducted to identify the hypocholesterolemic peptide derived from soybean protein with screening systems in vitro. One of the in vitro screenings to identify this hypocholesterolemic peptide is an evaluation system based on increases in LDL-receptor mRNA in HepG2 cells. In this system, a candidate for hypocholesterolemic peptide FVVNATSN was found to increase LDLreceptor mRNA, but without corroborative evidence from animal experiments in vivo. 22) Another in vitro screening to identify the hypocholesterolemic peptide evaluated the increase in cholesterol 7-hydroxylase (CYP7A1) mRNA in HepG2 cells in vitro. In this system, a mixture of milk casein peptides was found to increase CYP7A1 mRNA, but without corroborative evidence from animal experiments in vivo. 23) Our group, meanwhile, has found a novel hypocholesterolemic peptide lactostatin, IIAEK, increases CYP7A1 mRNA in vitro, while exerting a serum cholesterol-lowering action in in vivo experiments conducted in rats in parallel. 24, 25) Another process of in vitro screening to identify the hypocholesterolemic peptide evaluated the micellar solubility of cholesterol and bile-acid binding ability in vitro; the same parameters examined in this study. Based on earlier animal experiments in vivo and assays of the micellar solubility of cholesterol and bileacid binding ability in the presence of soy protein peptic hydrolysate (SPH) in vitro, our group has proposed that suppression of cholesterol absorption by direct interaction between cholesterol-mixed micelles and SPH in the intestinal epithelia contributes to the hypocholesterolemic action induced by SPH. 13) Convinced that SPH must contain a yet-to-be-identified peptide inhibits cholesterol absorption, we hypothesized that VAWWMY induces inhibition of cholesterol absorption in vivo by inhibiting the micellar solubility of cholesterol via its high bile-acid-binding capacity in vitro, as proposed in our previous report. 13) Soybean protein studies conducted to date, have yielded no direct in vivo evidence that the specific soybean peptide contributes to the inhibitory action of cholesterol absorption induced by soybean protein feeding.
In the present study, we evaluated the effects of the VAWWMY peptide on cholesterol absorption by measuring 3 H-cholesterol in rats and conducting in vitro assays on the micellar solubility of cholesterol and bileacid binding in the presence of VAWWMY. Our previous studies 13, 26) suggest that the extent of fecal steroid excretion depends on the degree of cholesterol absorption in vivo as measured by the 3 H-cholesterol method used in this study. Thus, our method for the evaluation of cholesterol absorption using 3 H-cholesterol in this study reflects in vivo cholesterol absorption in rats. Our results suggest that the VAWWMY peptide confers high bile acid-binding ability and stronger inhibition of the micellar solubility of cholesterol than CTH. We also found, for the first time, that the VAWWMY peptide suppresses cholesterol absorption in rats in vivo. Thus, the present study indicates that VAWWMY has an effect in inhibiting cholesterol absorption in vivo via inhibition of the micellar solubility of cholesterol with high bileacid binding capacity in vitro.
Cholesterol is rendered soluble in bile-salt mixed micelles and then absorbed. 27) Thus bile acids play an important role in cholesterol absorption. Cholestyramine, a high bile-acid binding polymer, suppresses cholesterol absorption and reduces the plasma cholesterol concentration. 28) Cholestyramine is used as a medicine for hypercholesterolemic patients. We have found that VAWWMY peptide has bile-acid binding ability equal to the medicine cholestyramine in vitro, and that it suppressed cholesterol absorption as compared to SPH and CTH in rats in vivo. Thus the VAWWMY peptide shows promise as a target molecule for the development of a new medication for hypercholesterolemia.
In conclusion, the present study provides the first direct in vivo evidence that a peptide with high bile-acid binding capacity, soystatin, contributes to the inhibitory action of cholesterol absorption. Now that the present study has confirmed the bile-acid binding ability of soystatin in vitro, the molecular mechanism of the binding of the taurocholic acid molecule to the soystatin molecule will perhaps be clarified in the near future. By elucidating the molecular mechanisms underlying bileacid binding to soystatin, we should be able to improve soystatin activity and create a novel bile-acid binding peptide. Ultimately, these findings and principles should promote the development of new functional foods and anti-atherogenic drugs.
